Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Jefferies Virtual London Healthcare Conference Transcript

Nov 18, 2020 / 06:10PM GMT
Release Date Price: $77.4
Eun Kyung Yang
Jefferies LLC, Research Division - MD & Senior Equity Research Analyst

Good morning and good afternoon. This is Eun Yang, one of the biotech analysts at Jefferies. Our next presenting company is BioMarin. Presenting from BioMarin is J.J. Bienaimé, Chairman and CEO; as well as Brian Mueller, CFO of the company.

So before we go into Q&As, J.J. is going to provide us an overview and opening remarks. J.J.?

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

So yes, thank you, Eun. We appreciate the opportunity to participate today. As you know, we recently shared our third quarter results, where we provided a number of updates. On the financial side, we tightened our GAAP net income guidance, and we improved our non-GAAP income guidance for 2020. And we slightly adjusted our total revenue guidance for the full year, mainly due to the delay in the potential approval of ROCTAVIAN. So we are optimistic that long-term data with ROCTAVIAN will ultimately lead to potential approval should the data

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot